Jump to Main Content
- Lybaert, Lien, et al. Show all 4 Authors
- Journal of controlled release 2018 v.289 pp. 125-145
- T-lymphocytes; cancer vaccines; cytotoxicity; disease course; immune response; nanoparticles; neoplasms; patients; probability; vaccination
- ... During the last decade anti-tumor immune-therapy has opened novel opportunities to efficiently combat cancer progression. The introduction of DC- and CAR T-cell based therapies as well as the successful application of antibody-based inhibitor of immune checkpoints (CTLA-4, PD1 and PDL1) have boosted the field and led to an overall benefit for many patients. In situ cancer vaccination is an attract ...